Abbott Laboratories (NYSE: ABT) grants director 2,286 RSUs

Q: What did Abbott Laboratories (ABT) report in this Form 4 filing?

Abbott Laboratories reported that director Sally E. Blount received a grant of 2,286 restricted stock units . These units were awarded under the company’s 2017 Incentive Stock Program and are payable in Abbott common shares upon specific future events.

Q: How many Abbott (ABT) shares does Sally E. Blount hold after this grant?

After the grant, Sally E. Blount’s direct holdings total 36,344 common shares of Abbott. This figure reflects her position immediately following the award of 2,286 restricted stock units disclosed in the Form 4 insider transaction report.

Q: What are the terms of the restricted stock units granted to the Abbott director?

The 2,286 restricted stock units will be paid on a one-to-one basis in Abbott common shares. Payment occurs on the earlier of the director’s separation from service, death, or the occurrence of a change in control as defined in the 2017 Incentive Stock Program.

Q: Under which plan were the Abbott (ABT) restricted stock units granted?

The restricted stock unit award was granted under the Abbott Laboratories 2017 Incentive Stock Program . This program governs how such equity awards are structured, including when units convert into Abbott common shares for the participating director.

Q: Does this Abbott Form 4 reflect a market purchase or sale of shares?

No, the Form 4 reflects a grant or award acquisition coded as “A,” not an open-market trade. The director received 2,286 restricted stock units as part of compensation, with no price per share reported for this non-market transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Blount Sally E. reported acquisition or exercise transactions in this Form 4 filing.

ABBOTT LABORATORIES director Sally E. Blount received a grant of 2,286 restricted stock units under the Abbott Laboratories 2017 Incentive Stock Program. Each unit will be paid in one Abbott common share on the earlier of her separation from service, death, or a defined change in control. Following this award, she holds 36,344 common shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Blount Sally E.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common shares without par value	2,286	$0.00	--

Holdings After Transaction: Common shares without par value — 36,344 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Restricted stock units granted: 2,286 units Shares following transaction: 36,344 shares Price per share for grant: $0.00 per share +1 more

4 metrics

Restricted stock units granted 2,286 units Grant to director Sally E. Blount on April 24, 2026

Shares following transaction 36,344 shares Total common shares directly held after award

Price per share for grant $0.00 per share Compensation-related award with no purchase price

Transaction code A (grant, award, or other acquisition) Non-derivative acquisition reported on Form 4

Key Terms

Restricted stock unit, 2017 Incentive Stock Program, change in control, Form 4

4 terms

Restricted stock unit financial

"Restricted stock unit award granted under the Abbott Laboratories 2017 Incentive Stock Program"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2017 Incentive Stock Program financial

"award granted under the Abbott Laboratories 2017 Incentive Stock Program (the "Program")"

change in control financial

"the occurrence of a change in control (as defined in the Program)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/28/2026 - 06:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blount Sally E.

(Last)

(First)

(Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK

ILLINOIS

60064

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common shares without par value	04/24/2026		A		2,286⁽¹⁾	A	$0	36,344	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Restricted stock unit award granted under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ Sally E. Blount by Jessica H. Paik, Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Abbott Laboratories (ABT) report in this Form 4 filing?

Abbott Laboratories reported that director Sally E. Blount received a grant of 2,286 restricted stock units. These units were awarded under the company’s 2017 Incentive Stock Program and are payable in Abbott common shares upon specific future events.

How many Abbott (ABT) shares does Sally E. Blount hold after this grant?

After the grant, Sally E. Blount’s direct holdings total 36,344 common shares of Abbott. This figure reflects her position immediately following the award of 2,286 restricted stock units disclosed in the Form 4 insider transaction report.

What are the terms of the restricted stock units granted to the Abbott director?

The 2,286 restricted stock units will be paid on a one-to-one basis in Abbott common shares. Payment occurs on the earlier of the director’s separation from service, death, or the occurrence of a change in control as defined in the 2017 Incentive Stock Program.

Under which plan were the Abbott (ABT) restricted stock units granted?

The restricted stock unit award was granted under the Abbott Laboratories 2017 Incentive Stock Program. This program governs how such equity awards are structured, including when units convert into Abbott common shares for the participating director.

Does this Abbott Form 4 reflect a market purchase or sale of shares?

No, the Form 4 reflects a grant or award acquisition coded as “A,” not an open-market trade. The director received 2,286 restricted stock units as part of compensation, with no price per share reported for this non-market transaction.